Sunday, November 15, 2026

EUR/CHF Bearish Momentum: 0.83% Down In The Last 5 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

EUR/CHF Bearish Momentum: 0.83% Down In The Last 5 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 0.83% for the last 5 sessions. At 14:06 EST on Thursday, 18 July, EUR/CHF (EURCHF) is $0.97.

EUR/CHF's yearly highs and lows, it's 7.032% up from its 52-week low and 2.669% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.18%, a positive 0.05%, and a positive 0.24%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.25% (last week), 0.24% (last month), and 0.24% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

Previous days news about EUR/CHF (EURCHF)

  • Eur/chf is set to move towards 0.96 on a 1-to-3-month view: rabobank. According to FXStreet on Tuesday, 16 July, "Risk of jitters around French politics and its budget we see risk of dips in EUR/CHF towards 0.96 on a 1-to-3-month view, Rabobank's Senior FX Strategist Jane Foley notes.", "Despite this year's modest weakening in the value of the CHF, EUR/CHF has been in a downtrend since 2007. "

More news about EUR/CHF (EURCHF).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Sources reconciled: no open conflicts right now.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com